Overview

Multiple Ascending Dose Phase 1 Study of ALA-3000

Status:
RECRUITING

Trial end date:
2025-10-27

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, multiple-dose study of ALA-3000 designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy in subjects with treatment-resistant depression (TRD).

Phase:

PHASE1

Details

Lead Sponsor:

Alar Pharmaceuticals Inc.

Treatments:

Duloxetine Hydrochloride
Escitalopram
Sertraline